Liberty Wealth Management LLC grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 143.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,821 shares of the medical research company’s stock after acquiring an additional 1,073 shares during the period. Liberty Wealth Management LLC’s holdings in Amgen were worth $336,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. Thoroughbred Financial Services LLC bought a new position in Amgen during the 4th quarter valued at $1,804,000. RMB Capital Management LLC boosted its stake in Amgen by 0.5% during the 4th quarter. RMB Capital Management LLC now owns 85,770 shares of the medical research company’s stock valued at $16,697,000 after purchasing an additional 455 shares in the last quarter. BOKF NA boosted its stake in Amgen by 70.6% during the 4th quarter. BOKF NA now owns 122,205 shares of the medical research company’s stock valued at $23,790,000 after purchasing an additional 50,559 shares in the last quarter. Finally, Kings Point Capital Management boosted its stake in Amgen by 22.7% during the 4th quarter. Kings Point Capital Management now owns 27,494 shares of the medical research company’s stock valued at $5,352,000 after purchasing an additional 5,083 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen stock opened at $196.25 on Friday. The firm has a market capitalization of $110.07 billion, a PE ratio of 13.63, a PEG ratio of 2.15 and a beta of 1.19. The stock has a fifty day simple moving average of $181.68. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $210.19.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be issued a dividend of $1.45 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.96%. Amgen’s dividend payout ratio is 40.28%.
In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the completion of the sale, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the sale, the director now owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,425 shares of company stock valued at $804,312. 0.25% of the stock is owned by corporate insiders.
A number of brokerages have issued reports on AMGN. BMO Capital Markets set a $230.00 price target on Amgen and gave the company a “buy” rating in a research note on Wednesday, July 31st. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley reduced their price objective on Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. JPMorgan Chase & Co. reissued a “hold” rating and set a $190.00 price objective on shares of Amgen in a research note on Wednesday, May 15th. Finally, Oppenheimer set a $210.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Friday, May 24th. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $210.41.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Why is cost of goods sold important?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.